Today in Biology — Oct 17

[THEO] Alright, picture this: you're trying to build something incredibly intricate, something that has to work perfectly at a molecular scale. Now imagine you have a digital assistant, a super-smart one, that can help you design every single atom. That's kind of the vibe around one of the biggest stories right now.

[DR. MARA] Indeed, Theo. The Department of Energy just announced the latest round of awards for their Genesis Mission. This initiative is about pushing the boundaries of what they're calling "Super Intelligence for Science" – essentially, massively accelerating AI's role in scientific discovery, particularly in areas like advanced materials, clean energy, and, of course, biology.

[THEO] "Super Intelligence for Science"— I like that. So, what does that actually mean for, say, someone trying to engineer a new bug to break down plastics? Or, you know, design a better enzyme?

[DR. MARA] It means a significant increase in computational power and specialized AI tools being directed at those exact problems. The Genesis Mission is awarding larger grants this time, explicitly to develop and deploy AI systems that can handle the complexity of, for example, designing novel biomolecules atom by atom. There’s a lot of chatter online about tools like RFdiffusion3, a new generative AI system that promises to do just that – design proteins and nucleic acids with precise functions.

[THEO] Atom by atom? That’s… almost mind-bending. Like trying to build a LEGO sculpture the size of a city, but you’re designing every single brick, its shape, its color, its connection points, all at once. And you're doing it with AI help. What's the practical upshot there?

[DR. MARA] The practical upshot is the potential to engineer biology in ways we previously couldn't imagine. Think about designing enzymes that perform reactions with unprecedented efficiency or specificity, or creating therapeutic proteins that target diseases precisely. For engineering non-model organisms, it could mean rapidly designing new genetic circuits or metabolic pathways without the usual trial-and-error bottlenecks.

[THEO] That's huge for engineering biology, especially if we're trying to get these complex systems working in organisms we don't know much about. So, Genesis is one big push. What else is shaping the landscape right now?

[DR. MARA] Right on its heels, ARPA-H, the Advanced Research Projects Agency for Health, has launched its BIOGAMI program. This is another major initiative focused on finding and fixing protein dysfunction at the earliest stages.

[THEO] BIOGAMI. So, like a biological game plan? What's the target there?

[DR. MARA] The goal is early intervention in diseases by understanding and correcting protein misfolding or aggregation before significant pathology occurs. It’s about catching the problem at its molecular inception. This is critical for everything from neurodegenerative diseases to metabolic disorders, where protein malfunction is a key driver. It's a proactive approach to health, using advanced molecular detection and intervention strategies.

[THEO] So, Genesis is building the tools, and BIOGAMI is looking at how proteins go wrong and how to fix them early. Both seem to point towards a future where we have much finer control over molecular biology. And I saw something about the NSF, too?

[DR. MARA] Yes, the NSF has released a new X-Labs bioengineering funding opportunity. They’re inviting proposals from teams working to accelerate breakthroughs in bioengineering. It signals a dedicated push from the NSF to foster highly innovative, potentially high-risk, high-reward projects in the field.

[THEO] "X-Labs" always sounds like where the cool stuff happens. More funding for bioengineering breakthroughs, big AI pushes from DOE, and ARPA-H tackling protein dysfunction. It feels like the national initiatives are all converging on this idea of precise, engineered biological solutions, often with AI at the core.

[DR. MARA] It’s certainly a clear trend, Theo. The increased funding and strategic focus from these agencies underscore a collective belief that the next major advancements in medicine, energy, and environmental solutions will emerge from our ability to precisely engineer biological systems. And AI is increasingly seen as the essential accelerator for that work.

[THEO] Fascinating. It'll be interesting to see what these AI-driven tools build first.